Does low thyroid hormone signaling increase LDL particle number and ApoB by reducing hepatic LDL receptor–mediated clearance?

Thyroid hormone (TH) serves as a primary metabolic regulator of cholesterol homeostasis. In states of low thyroid signaling, such as clinical or subclinical hypothyroidism, the liver’s ability to clear atherogenic lipoproteins from the blood is significantly impaired, leading to a marked increase in cardiovascular risk markers.

Clinical and effectiveness evidence

Clinical research consistently demonstrates that diminished thyroid signaling results in elevated levels of Apolipoprotein B (ApoB) and an increased LDL particle number (LDL-P).

• Lipoprotein accumulation: Hypothyroidism is characterized by a reduced fractional catabolic rate (FCR) of LDL particles, meaning these particles circulate longer in the bloodstream.
• Reversibility: Longitudinal studies show that thyroid hormone replacement therapy (levothyroxine) effectively reverses these elevations. Treatment stimulates receptor-mediated clearance, shifting the lipoprotein profile toward a less atherogenic state and lowering total LDL-P and ApoB concentrations.
• Correlation with TSH: Evidence from large cohort studies shows that ApoB—the primary protein component of all potentially atherogenic particles—correlates positively with thyroid-stimulating hormone (TSH) levels, even within the high-normal range.

Mechanistic explanations

The primary mechanism driving these changes is the downregulation of hepatic low-density lipoprotein receptors (LDLR).

• SREBP-2 Pathway: Triiodothyronine (T3) regulates the LDLR gene primarily through the sterol regulatory element-binding protein-2 (SREBP-2). T3 facilitates the maturation and nuclear translocation of SREBP-2, which then binds to the LDLR promoter to drive transcription. Low T3 levels disrupt this process, reducing LDLR expression.
• PCSK9 Interaction: Recent data suggest that thyroid hormone signaling also influences levels of PCSK9, a protein that targets LDL receptors for degradation. In low thyroid states, PCSK9 levels may remain elevated, further reducing the density of available receptors on the surface of hepatocytes.
• ApoB Secretion: Beyond clearance issues, low thyroid signaling may increase the hepatic secretion of VLDL-ApoB-100, the metabolic precursor to LDL, contributing to a higher total volume of atherogenic particles.

Bottom line

Low thyroid hormone signaling directly increases LDL particle number and ApoB by reducing hepatic LDL receptor activity, primarily via the SREBP-2 transcription pathway, which impairs the clearance of atherogenic lipoproteins.